About Us

Inspired by nature, motivated by health

At inSoma Bio we borrow nature’s own designs to develop unique products for reconstructive plastic surgery. Our product enables surgeons to use a person’s own tissue instead of synthetic implants and fillers to improve procedures like breast and facial reconstruction.

DNA Decoration
About us

Our Mission

The best possible patient outcomes for reconstructive plastic surgeries like breast reconstructive occur when a person’s own tissue can be used to rebuild or replace tissue. Founded by a team of biomedical engineers and clinicians with a combined 60 years of domain expertise, inSoma is developing injectable materials designed to mimic human tissue that can be used to more safely and accurately rebuild a person’s tissue without the need for synthetic implants or fillers.

The Team

Founders

Stefan Roberts, PhD

Chief Executive Officer

Dr. Roberts has worked in biomaterials design and development for a decade. He has a BS in Biomedical Engineering from Washington University in St. Louis and a PhD from Duke University where he developed inSoma’s foundational technology as part of his dissertation. Stefan’s motivation to translate scientific work to clinical practice originates from prior positions he has held at St. Jude Children’s Research Hospital and Barnes Jewish Hospital.

Ashutosh Chilkoti, PhD

Chairman

Dr. Chilkoti is the chair of the Biomedical Engineering Dept. at Duke University where he has pioneered the academic and industrial application of recombinant proteins with over 400 publications and 70 patents in this field. In addition, he is founder of multiple startup companies with successful exits including one publicly traded company, PhaseBio Pharmaceuticals, that has taken drug delivery technology into Phase 2 clinical trials.

Scott Hollenbeck, MD

Lead Medical Advisor

Dr. Hollenbeck is a board certified Plastic and Reconstructive surgeon with two decades of expertise in clinical practice over 100 peer-reviewed publications. He serves as Vice Chair of Research and Director of Breast Reconstruction with the Duke Division of Plastic and Maxillofacial Surgery.

The Team

Team members

June Almenoff, MD, PhD, FACP

Director

Previously serving as President and Principal Executive Officer at Furiex (Acquired by Actavis for $1.2B), COO and CMO of Innovate Biopharmaceuticals, and with 13 years in GSK’s R&D, June brings significant experience guiding technologies from pre-clinic to product, including development of regulatory and commercial strategy.

Larry Woolhiser, MBA, CPA

Chief Financial Officer

Larry is a results-driven MBA and CPA with 20+ years of CFO, Controllership, and Treasury leadership experience with entrepreneurial, high growth, and transitioning healthcare and technology companies. Larry has a track record of being a catalyst for change, innovation, and growth backed by a solid history of transforming robust business goals into strategies for unlocking value and driving strong top and bottom-line results.

Matthew Anderson, MS

Fermentation Scientist

Matthew received his B.S. from the University of Miami and M.S. from University of South Florida, obtaining a degree in Biology/Microbiology. For the past 15 years he has worked in natural products discovery from bacteria, specializing in microbial growth/isolation and fermentation, as well as downstream purification processes for proteins and polysaccharides.

Eric Van Gorder, MS

Research Scientist

Eric has over six years of research experience spanning academic and cGMP private sector labs, including extensive analytical work in pharmaceutical production settings. He has a BS in Chemistry and an MS in Biology from Southeastern Louisiana University.

Mahsa Taskindoust, BS

Fellowship Scholar

Mahsa has a BS from Duke University where is also currently completing her MD. Planning her career as a plastic surgeon, Mahsa is completing a specialty research fellowship in plastics under the guidance of Dr. Hollenbeck.